Friday's news was great. The commentary from many on Twitter was not.
Everything in the RNS has been in the public domain for 6 months - except on thing: ESL has been granted an extra 6 months to become an investing Co or complete an RTO. 1/9
The reaction on Friday, and indeed the drop in the SP this AM, is indicative of the absence of research being carried out on even the most basic of levels by many investors. It is worrying that many don't really know what they're holding 2/9
With regard to #ESL itself - DBAY essentially acquired a controlling 51% stake in the operations (at subsid. level) for £55m. This values the business at £108m, and ESL's 49% stake at £53m, or 14.0p per share.
Now, a discount should be incorporated into the value of ESL's... 3/9
...stake, as we must account for i) the future dilution to the stake incurred by the PIK interest due to DBAY, and ii) the non-controlling nature of the holding.
Conversely, we could argue that there should now be a premium attributed to it: firstly, the DBAY funding price...4/9
...was at an EXTREME discount to pre-suspension levels. It was rescue funding, and DBAY had #ESL at its mercy.
Secondly, as I have tweeted about in the past, through a combo of massive grocery volumes and v low fuel prices, business should be very strong ATM. 5/9
Last month, Adrian Collins joined #ESL as chairman. He is a genuine industry heavyweight in UK investment management. Just look at his CV.
Now. Would he have taken the position if there was a chance that the Co would be delisted only 8 weeks after he joined? Of course not. 6/9
He'd have sought assurances from regulators that he'd get a 6 month extension to either raise £6m+ and become an investing company, or else carry out an RTO.
Given his background, I think the former will be his preference. He now has 7 months to raise it - a lifetime on AIM. 7/9
Ultimately, IMO the 49% stake in the Eddie ops will be sold to DBAY too. It could even be partially disposed of, to raise the £6m minimum cash requirement to become an IC. This would obviously negate the need for a placing, and leave #ESL with a meaningful holding in Eddie. 8/9
DBAY and the new team at Eddie have a track record of success: the environment is favourable now (high volumes from customers and low fuel prices) to turn the business around.
Meanwhile, #ESL's heavyweight chair will be able to plot a new course for the Co and its investors. 9/9
• • •
Missing some Tweet in this thread? You can try to
force a refresh
There are many stale holders who have been underwater for 18+ months, who will be happy to take some cash out now, in this ongoing cost of living crisis. That is understandable.
There will also be traders exiting, having positioned for this update.
Furthermore, the...
2/20
...wider investment community has not yet heard of, and even more so not appreciated the significance of, today's news at #AVCT.
Finally, I will state with a high degree of confidence that today's RNS opens the floodgates for numerous more updates in the near future.
Volume returning really nicely to the small cap space, which is creating excellent trading conditions.
My average holding period in the Short-term Trading Portfolio is still around 16 sessions / 3 weeks.
Seemingly contrary to many, I consider trade entries based both on..
2/18
...fundamentals (see two recent successful trades in MMAG and SPEC, with rationales for trades founded on earnings metrics), and on stories and associated sentiment (BSFA being most recent example).
I don't subscribe to only utilizing one or the other; the same way as I...
@AnEarlofWisdom Hi Earl, I can't see any of the posts, as I'm blocked by those accounts (or I've blocked!), but I've been told there's a lot of scaremongering about various things:
1) Delay in trial; 2) Dox not activating much in TME; 3) Low cash balance, and thus possible placing coming.
1/8
@AnEarlofWisdom On the contrary, except for Cohorts 1 and 2 taking longer than expected (due to patient withdrawals - nothing whatsoever to do with #AVA6000 itself), #AVCT's progress in 2022 could not be stronger.
The DE to 200mg/m2 was the ultimate target, so that nullifies point 2) ⬆️.
2/8
@AnEarlofWisdom Licensing deals for targeted oncology drugs - even those at pre-clinical stage, like 3996 - have been monstrous in recent times (e.g. $100m cash upfront for an antibody-drug conjugate, just last month ⬇️).
...substrate to FAP is so high that the concentration ratio of active doxorubicin in the tumour : healthy tissue, will negate the requirement for increase in dose size. [My view!]
Enough dox is already becoming active in the tumour micro-environment, at the current...
3/8
$SGEN specializes in antibody-drug conjugates ('ADC') - a relatively novel form of targeted cancer treatment.
@avacta's targeted cancer treatment platform, preCISION, has the real potential of generating pro-chemotherapies that are MORE targeted than ADCs, and thus...
2/6
...also potentially capable of delivering a more potent drug payload.
#AVCT will be announcing the results of the first preCISION prodrug P1 trial (AVA6000) in the next few months.
Success will mean the platform could be used to modify many other existing chemotherapies.
3/6